HLS Therapeutics Inc (HLS) Stock Price & News

HLS:TSE

HLS Therapeutics Inc

CA$4.41

-0.68%

(-0.030) 1D

Nov 6, 4:00:00 PM GMT-5 · CAD

All symbols

	Symbol	Price	Change	% Change

Next call in 5 days

Thu, Nov 12, 4:30 PM

Fiscal period

Q3 2026

- / -$0.08

Revenue / Est. (USD)

- / 14.88M

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance: upcoming earnings

Insights from the latest news and reports

Previous reportsAll values in USD

Loading Previous Earnings...

All values in USD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	13.51M	15.20M	12.86M	14.67M
Cost of goods sold	3.81M	4.28M	4.19M	4.56M
Cost of revenue	3.81M	4.28M	4.19M	4.56M
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	4.78M	5.21M	5.21M	5.45M
Operating expense	11.08M	10.68M	10.89M	11.27M
Total operating expenses	14.88M	14.96M	15.08M	15.83M
Operating income	-1.37M	237.00K	-2.22M	-1.16M
Other non operating income	-534.00K	-517.00K	-87.00K	-73.00K
EBT including unusual items	-3.94M	-1.98M	-2.30M	-1.01M
EBT excluding unusual items	-3.94M	-1.98M	-2.30M	-1.01M
Income tax expense	-17.00K	-647.00K	2.00K	13.00K
Effective tax rate	0.43%	32.64%	-0.09%	-1.29%
Other operating expenses	-	-	-	-
Net income	-3.92M	-1.34M	-2.30M	-1.02M
Net profit margin	-29.00%	-8.79%	-17.86%	-6.95%
Earnings per share	-0.12	-0.04	-0.07	-0.03
Interest and investment income	24.00K	18.00K	12.00K	4.00K
Interest expense	-2.44M	-897.00K	-801.00K	-748.00K
Net interest expenses	-2.42M	-879.00K	-789.00K	-744.00K
Depreciation and amortization charges	5.51M	5.46M	5.54M	5.53M
EBITDA	4.14M	5.18M	3.32M	4.37M
Gain or loss from assets sale	-	-	-	-

Finance